

CUMBERLAND PHARMACEUTICALS INC  
Form 8-K  
May 09, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 9, 2014 (May 6, 2014)

Cumberland Pharmaceuticals Inc.

---

(Exact name of registrant as specified in its charter)

Tennessee (State or other jurisdiction of incorporation)	001-33637 (Commission File Number)	62-1765329 (I.R.S. Employer Identification No.)
--	---------------------------------------	--

2525 West End Avenue, Suite 950, Nashville, Tennessee (Address of principal executive offices)	37203 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (615) 255-0068  
Not Applicable

---

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events

On May 6, 2014, Cumberland Pharmaceuticals Inc. (the "Company") and China's Gloria Pharmaceuticals Co. issued a press release announcing a joint research and development initiative. A copy of the press release is furnished as Exhibit 99.1.

On May 6, 2014 the Company issued a press release announcing the launch of its active promotional campaign to support its new Vaprisol<sup>®</sup> product. A copy of the press release is furnished as Exhibit 99.2.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 9, 2014

Cumberland Pharmaceuticals Inc.

By: Rick S. Greene

Name: Rick S. Greene  
Title: Chief Financial Officer

---

Exhibit Index

Exhibit No.	Description
99.1	Press release dated May 6, 2014
99.2	Press release dated May 6, 2014